Reduce drug approval costs
The pharmaceutical product approval cycle requires manufacturers to demonstrate the economic usefulness of new products, in addition to their clinical efficacy. This may involve testing these products on a large scale, on thousands of patients and over several years. How can we shorten this cycle and reduce cohort costs? For a major European pharmaceutical company, we modeled and tested the impact of a new medical test on the care pathway of two digital cohorts. We created this with our Societal Digital Matching© technology. We completed the assignment in three months, at a cost of less than 5% of that of a real cohort.